Fresh perspectives in chronic constipation and other functional bowel disorders

Reviews in Gastroenterological Disorders

Volumn 7, Issue 3, 2007, Pages 116-133

  Cash, Brooks D ^a   Chang, Eugene ^b   Talley, Nicholas J ^c   Wald, Arnold ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Chloride channels; Constipation; Irritable bowel syndrome; Rome III

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BICARBONATE; BULKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CHLORIDE; CHLORIDE CHANNEL; CHOLECYSTOKININ; ENKEPHALIN; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM HYDROXIDE; NEUROKININ A; NITRIC OXIDE; PLACEBO; PROBIOTIC AGENT; PROSTAGLANDIN E1; RIFAXIMIN; SEROTONIN; SEROTONIN AGONIST; SORBITOL; SUBSTANCE P; TACHYKININ; TEGASEROD; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; BIFIDOBACTERIUM ANIMALIS; BLOATING; CASE REPORT; CHLORIDE TRANSPORT; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC TEST; DIARRHEA; DISEASE CLASSIFICATION; EMPIRICAL RESEARCH; ENTEROPATHY; FEEDBACK SYSTEM; FLATULENCE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOVOLEMIA; IRRITABLE COLON; LACTOBACILLUS CASEI; MALE; MUSCLE CRAMP; NAUSEA; OUTCOMES RESEARCH; PELVIC ORGAN PROLAPSE; REVIEW; SYMPTOMATOLOGY;

ADULT; ALPROSTADIL; CATHARTICS; CHLORIDE CHANNELS; CHRONIC DISEASE; CLINICAL PROTOCOLS; CONSTIPATION; DEFECATION; FATTY ACIDS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MANOMETRY; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 34848858965     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med. 1995;123:688-697.
2. Drossman DA, sr ed. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006.
3. Camilleri M. Functional gastrointestinal disorders: novel insights and treatments. Medscape General Medicine Web site. http://www. medscape.com/viewarticle/407938. Published November 1, 1999. Accessed August 1, 2007.
4. Thompson WG. The road to Rome. Gastroenterology. 2006;130:1552-1556.
5. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
7. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-924.
8. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl 2):1143-1147.
9. Rao SSC. Constipation: evaluation and treatment. Gastroenterol Clin North Am. 2003;32:659-683.
10. Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1778.
11. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360-1368.
12. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol. 1999;94:609-615.
13. Foxx-Orenstein A. IBS-review and what's new. MedGenMed. 2006;8:20.
14. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional Gl disorders. Gastroenterology. 2007;132:397-414.
15. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998;115:370-380.
16. Kim D-Y, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 2000;95:2698-2709.
17. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7(8 suppl):S252-S260.
18. Lacy BE, Yu S. Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol. 2002;34:27-33.
19. Streutker CJ, Huizinga JD, Driman DK, Riddell RH. Interstitial cells of Cajal in health and disease. Part II: ICC and gastrointestinal stromal tumours. Histopathology. 2007;50:190-202.
20. He C-L, Burgart L, Wang L, et al. Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. Gastroenterology. 2000; 118:14-21.
21. Prather CM. Subtypes of constipation: sorting out the confusion. Rev Gastroenterol Disord. 2004;4(suppl 2):S11-S16.
22. Harrell LE, Chang EB. Intestinal water and electrolyte transport. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease e-dition: Pathophysiology, Diagnosis, Management. 8th ed. Philadelphia, PA: Saunders; 2005: Chapter 96.
23. Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic Fibrosis. Pediatrics. 1986;78:473-479.
24. Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil. 2007;19:4-10.
25. Physicians' Desk Reference. 61st ed. Montvale, NJ; Thomson PDR; 2007.
26. Drugs, supplements, and herbal information. Medline Plus Web site. http://www.nlm.nih.gov/ medlineplus/druginformation.html. Updated June 5, 2007. Accessed August 9, 2007.
27. Ambizas EM, Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007;41:957-964.
28. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287: C1173-C1183.
29. Lacy BE, Campbell Levy L. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41:345-351.
30. Cash BD, Chang L, Sabesin SM, Vitat P. Update on the management of adults with chronic idiopathic constipation. J Fam Pract. 2007;56 (suppl):S1-S8.
31. Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(suppl 1):S5-S21.
32. Remes-Troche JM, Rao SSC. Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep. 2006;8:416-424.
33. Agrawal S, Bhupinderjit A, Bhutani MS, et al. Committee of Minority Affairs and Cultural Diversity, American College of Gastroenterology. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515-523.
34. Rao SSC, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005;100: 1605-1615.
35. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2004;126: 57-62.
36. Thornton MJ, Lubowski DZ. Assessment of the constipated patient: an overview. In: Wexner SD, Zbar P, Pescatori M, eds. Complex Anorectal Disorders: Investigation and Management. London: Springer; 2005:412-428.
37. MiraLAX®, number one doctor-prescribed laxative, now available over the counter. Schering-Plough Web site. http://www.schering-plough. com/schering_plough/news/release.jsp?releaseID= 978827. Published March 28, 2007. Accessed August 3, 2007.
38. FDA public health advisory: tegaserod maleate (marketed as Zelnorm). US Food and Drug Administration Web site. http://www.fda.gov/ cder/drug/advisory/ tegaserod.htm. Published March 30, 2007. Accessed August 9, 2007.
39. FDA permits restricted use of Zelnorm for qualifying patients. US Food and Drug Administration Web site. http://www.fda.gov/bbs/topics/NEWS/ 2007/NEW01673.html. Published July 27, 2007. Accessed August 9, 2007.
40. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S7-S26.
41. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005; 100:232-242.
42. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936-971.
43. Physicians' Desk Reference. 59th ed. Montvale, NJ: Thomson PDR; 2005.
44. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441.
45. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608.
46. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol. 2004; 38:776-781.
47. Guidelines for the evaluation of probiotics in food. World Health Organization Web site. http://www. who.int/foodsafety/publications/ fs_management/ probiotics2/en/index.html. Accessed August 9, 2007.
48. Fernández-Bañares F. Nutritional care of the patient with constipation. Best Pract Res Clin Gastroenterol. 2006;20:575-587.
49. Bouvier M, Meance S, Bouley C, et al. Effects of consumption of a milk fermented with the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Biosci Microflora. 2001:20:43-48.
50. Posserud I, Stotzer P-O, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56: 802-808.
51. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419.
52. Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-1301.
53. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333.
54. Simren M, Stotzer P-O. Use and abuse of hydrogen breath tests. Gut. 2006;55:297-303.
55. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942-G947.
56. Johanson JF, Gargano MA, Holland PC, Patchen ML. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week phase III study [abstract]. Am J Gastroenterol. 2005;100(suppl 9):S324.
57. Johanson JF, Gargano MA, Holland PC, et al. Phase III safety and efficacy of RU-0211, a chloride channel activator, for the treatment of constipation [abstract]. Gastroenterology. 2003;124 (4 suppl 1):A-48.
58. Ueno R, Wahle A, Panas R, et al. Evaluation of safety and efficacy in a twelve-month study of lubiprostone for the treatment of chronic idiopathic constipation [abstract]. Am J Gastroenterol. 2006;101(suppl 2):S491.
59. Crowell MD, Harris LA, DiBlaise JK, Olden KW. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs. 2007; 8:66-70.
60. Sucampo Pharmaceuticals submits supplemental new drug application for lubiprostone to treat irritable bowel syndrome with constipation. Sucampo Pharmaceuticals Web site. http:// investor.sucampo.com/phoenix.zhtml?c=201197 &p=irol-newsArticle&ID-1032666&highlight=. Published July 12, 2007. Accessed August 9, 2007.
61. Drossman DA, Chey W, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double-blind trials [abstract]. Gastroenterology. 2007;132: 2586-2587.
62. Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428-441.
63. Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657-664.
64. Johanson JF, Panas R, Holland PC, Ueno R. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS) [abstract]. Gastroenterology. 2006;130(4 suppl 2): A-25.
65. Prather CM. Pregnancy-related constipation. Curr Gastroenterol Rep. 2004;6:402-404.
66. Becker D, Compagnone D, Lu L. Lactulose in the treatment of constipation in pregnant Chinese women: a double-blind, randomized, placebo-controlled, multicenter study [abstract]. Gastroenterology. 2006;130(4 suppl 2):A-599-A-600.
67. Engelke K, Harris S, Roerig B, Ueno R. Effect of lubiprostone, a novel type-2 chloride channel (Clc-2) activator, in pregnant rhesus monkeys [abstract]. Gastroenterology. 2007;132(4 suppl 2): A-534.
68. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. An open-label study of chronic polyethylene glycol laxative use in chronic constipation. Aliment Pharmacol Ther. 2007;25:703-708.
69. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs non-elderly subjects [abstract]. Gastroenterology. 2006;130(4 suppl 2):A-189.
70. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation in elderly patients. Paper presented at: 71st Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology; October 20-25, 2006; Las Vegas, NV.
71. Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation [abstract]. Gastroenterology. 2007;132(4 suppl 2): A-191.
72. Corman ML. Colon and Rectal Surgery. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
73. Zutshi M, Hull TL, Trzcinski R, et al. Surgery for slow transit constipation: are we helping patients? Int J Colorectal Dis. 2007;22:265-269.
74. Treatment of pelvic floor dysfunction. Mayo Clinic Web site. http://www.mayoclinic.org/ constipation/treatment-pelvic-floor-dysfunction. html. Accessed August 9, 2007.